MIAMI & BARRANQUILLA, Colombia / Oct 02, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will host a webinar dedicated to the Colombian pharma market and its regulations on October 10th.
The Company will host a webinar at 10:00 a.m. Eastern time with Mariana Sarasti, Director of Pharmaceutical Industry Chamber within the National Business Association of Colombia (ANDI).
Mariana is an economist from The Chicago University, with a specialization in social economics from Universidad de los Andes and a master’s degree in public administration from Harvard University. She has extensive experience in business development and strategy, as well as in project planning and management in the public and private sectors.
To access the webinar, please use the following information:
Date: | Tuesday, October 10, 2023 |
Time: | 10:00 a.m. ET |
Webinar Link: |
The webinar will be broadcast live and available for replay via the investor relations section of Procaps’ website here.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
Last Trade: | US$1.68 |
Daily Change: | -0.32 -16.00 |
Daily Volume: | 28,505 |
Market Cap: | US$189.540M |
December 20, 2024 December 03, 2024 June 28, 2024 December 26, 2023 November 29, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load